The Global Rise of Hormone-Dependent Cancers
Breast cancer remains the most frequently diagnosed malignancy among women, with hormone receptor–positive (HR+) disease accounting for the majority of cases, while prostate cancer is the leading cancer among men in many countries. Aging populations, longer life expectancy, and widespread screening programs have contributed to higher detection rates, expanding the population eligible for long-term endocrine therapy in early and advanced disease settings.
Western and Northern European countries report earlier diagnoses due to organized screening and strong primary care systems, resulting in prolonged use of adjuvant hormone therapy. In Southern and parts of Central Europe, later-stage presentations are more common, increasing reliance on systemic endocrine treatment in metastatic disease. Despite these regional differences, hormone therapy remains a foundational treatment modality across Europe, embedded in national and international clinical guidelines.
Beyond breast and prostate cancer, other hormone-sensitive tumors, including certain endometrial and ovarian cancers, also contribute to endocrine therapy utilization. Improvements in pathology services and routine hormone receptor testing have refined patient selection and reinforced the role of hormone therapy as a standard of care.
Widespread Adoption of Combination Treatment Strategies
European oncology practice is characterized by the use of combination hormone therapy regimens, reflecting advances in clinical evidence and treatment personalization. In HR+ breast cancer, endocrine agents such as aromatase inhibitors or selective estrogen receptor modulators are frequently combined with ovarian suppression or additional systemic therapies to enhance disease control. This approach is adopted across academic and community oncology centers, supported by multidisciplinary care models.
Prostate cancer treatment has evolved, with androgen deprivation therapy combined with other hormonal agents or systemic treatments in patients with high-risk or advanced disease. European clinical guidelines encourage tailored treatment strategies based on disease stage, patient fitness, and response, driving consistent uptake of combination regimens across diverse healthcare systems.
The spread of combination hormone therapies is reinforced by strong professional networks, pan-European guideline harmonization, and ongoing clinician education. Cross-border collaboration and shared clinical standards enable rapid translation of evidence into practice, even as reimbursement and access vary by country. Combination hormone therapy has become an integral and increasingly sophisticated component of cancer care across Europe.
